Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 5:11:1437555.
doi: 10.3389/fcvm.2024.1437555. eCollection 2024.

Editorial: Reviews in bioresorbable scaffold

Vikrant Rai  1 , Juan F Iglesias  2 , Matthias Bossard  3 , Khagendra Dahal  4 , Chun Chin Chang  5 , Mariusz Tomaniak  6
Affiliations
Editorial

Editorial: Reviews in bioresorbable scaffold

Vikrant Rai et al. Front Cardiovasc Med. .
No abstract available

Keywords: bioresorbable scaffolds (BRS); coronary artery disease; drug-eluting stents (DES); percutaneous coronary intervention (PCI); revascularization.

PubMed Disclaimer

Conflict of interest statement

MB has received consulting and speaker fees from Abbott Vascular, Abiomed, Amarin, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daichii, MedAlliance, Mundipharma, Novartis, OM Pharma SA and SIS Medical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. (2020) 75(6):590–604. 10.1016/j.jacc.2019.11.058 - DOI - PubMed
    1. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. (2016) 134(2):168–82. 10.1161/CIRCULATIONAHA.116.021539 - DOI - PubMed
    1. Abellas-Sequeiros RA, Ocaranza-Sanchez R, Bayon-Lorenzo J, Santas-Alvarez M, Gonzalez-Juanatey C. 12-month clinical outcomes after magmaris percutaneous coronary intervention in a real-world cohort of patients: results from the CardioHULA registry. Rev Port Cardiol (Engl Ed). (2020) 39(8):421–5. 10.1016/j.repc.2019.09.018 - DOI - PubMed
    1. Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, et al. 5-year outcomes after bioresorbable coronary scaffolds implanted with improved technique. J Am Coll Cardiol. (2023) 82(3):183–95. 10.1016/j.jacc.2023.05.003 - DOI - PubMed
    1. Forrestal B, Case BC, Yerasi C, Musallam A, Chezar-Azerrad C, Waksman R. Bioresorbable scaffolds: current technology and future perspectives. Rambam Maimonides Med J. (2020) 11(2):e0016. 10.5041/RMMJ.10402 - DOI - PMC - PubMed

Publication types